查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542863

全球马凡氏症候群治疗市场 - 2024-2031

Global Marfan Syndrome Treatment Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球马凡氏症候群治疗市场于2023年达到2.035亿美元，预计到2031年将达到3.126亿美元，在2024-2031年预测期间复合年增长率为5.6%。

马凡氏症候群是一种遗传性疾病，会影响结缔组织，即支撑和固定器官和体内其他结构的纤维。马凡氏症候群最常影响心臟、眼睛、血管和骨骼。治疗方法取决于受影响的身体部位，可能包括药物、其他疗法和手术来控制病情及其併发症。治疗和手术方面的研究和进步使马凡氏症患者能够过着长寿、有生产力的生活。

市场动态：

驱动程式和限制

研究与开发的崛起

研发的成长是预测期内帮助整个市场成长的主要驱动因素之一。研究和开发正在透过新颖的成像方法、治疗标靶和机器学习模型来推进对马凡氏症候群的理解和治疗。

例如，2023 年 5 月的一项研究表明，纤维连接蛋白有可能治疗马凡氏症候群 (MFS) 患者的主动脉瘤。研究表明，MFS 中的整合素 a5B1 负责放大发炎反应，这为主动脉瘤提供了一种新的治疗方法。

与此综合征相关的副作用

马凡氏症候群影响身体的不同部位，可能会出现其他问题和併发症，包括身体主动脉（主动脉）扩大（动脉瘤），当主动脉壁变弱和凸出时就会发生这种情况。如果主动脉壁撕裂或破裂，这是危及生命的紧急情况。白内障是眼睛水晶体中的混浊区域。当脊髓周围的组织变弱和伸展时，就会发生硬脑膜扩张。

细分市场分析

全球马凡氏症候群治疗市场根据治疗类型、给药途径、最终用户和地区进行细分。

主动脉扩张治疗类型细分市场约占马凡氏症候群治疗市占率的37.3%

治疗型节段的主动脉扩张约占37.3%。马凡氏症候群是一种相对常见的结缔组织遗传性疾病，影响许多器官系统，但最严重的併发症是主动脉瘤和夹层。有多种药物和手术方法可用于治疗心血管併发症。

例如，2022 年8 月，马凡基金会称，对1442 名马凡氏症参与者进行的七项全球临床试验的荟萃分析发现，血管紧张素受体阻断剂（ARB）可显着降低患者主动脉根部扩大的比率。研究发现，氯沙坦和厄贝沙坦等 ARB 药物即使对于已经服用 β 受体阻断剂的患者也有效。在具有致病性 FBN1 基因突变的患者中，降低发生率的效果尤其显着，为此效果提供了生物学支持。

市场地域占有率

预计北美在整个预测期内将占据总市场份额的 38.4% 左右

由于美国马凡氏症候群患病率上升、治疗方案的进步、FDA 批准、新产品推出等因素，预计北美在整个预测期内将占据约 38.4% 的市场份额帮助该地区在预测期内实现增长。

例如，在威斯康辛州儿童医院，美国估计有 5 万人患有马凡氏症候群（即每 5,000 人中就有 3 人）。马凡氏症候群在男性和女性中的发生率相同，并且在所有种族和族裔群体中的发病率也相同。其发生率为两万分之一的活产婴儿。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 研究与开发的崛起
      • 慢性病盛行率上升
    • 限制
      • 与此综合征相关的副作用
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 专利分析
  • 大环境分析
  • SWOT分析
  • DMI 意见

第 6 章：按治疗类型

  • 主动脉扩张
  • 乙种肾上腺阻断剂
  • 钙通道阻断剂
  • ACE 阻断剂
  • 主动脉根部置换术
  • 阀门备用根部更换
  • 针对夹层和动脉瘤的复杂主动脉手术
  • 其他的

第 7 章：依给药途径分类

  • 口服
  • 注射用
  • 其他的

第 8 章：最终用户

  • 医院
  • 诊所
  • 其他的

第 9 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Mesa Science Associates Inc
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Merck & Co. Inc
  • Aurobindo Pharma USA
  • Teva Pharmaceuticals
  • Lupin Pharmaceuticals, Inc
  • AdvaCare Pharma (*LIST NOT EXHAUSTIVE)

第 12 章：附录

简介目录
Product Code: PH4325

Overview

Global Marfan Syndrome Treatment Market reached US$ 203.5 million in 2023 and is expected to reach US$ 312.6 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Marfan syndrome is an inherited disorder that affects connective tissue the fibres that support and anchor the organs and other structures in the body. Marfan syndrome most commonly affects the heart, eyes, blood vessels, and skeleton. Treatment varies depending on the area of the body affected and may include medications, other therapies, and surgery to manage the condition and its complications. Research and advances in treatments and surgeries allow people with Marfan syndrome to live long, productive lives.

Market Dynamics: Drivers & Restraints

Rise in research and development

The rise in research and development is one of the major driving factors that help the overall market to grow during the forecast period. Research and development are advancing the understanding and treatment of Marfan syndrome through novel imaging methods, therapeutic targets, and machine-learning models.

For instance, in May 2023, a study suggested that fibronectin can potentially treat aortic aneurysms in individuals with Marfan Syndrome (MFS). The research indicates that integrin a5B1 in MFS is responsible for amplifying inflammatory responses, suggesting a new treatment approach for aortic aneurysms.

Side effects associated with the syndrome

Marfan syndrome affects different areas of the body, other problems and complications can develop, including, enlargement (aneurysm) of the main artery in the body (aorta), which happens when the wall of the aorta weakens and bulges. It is a life-threatening emergency if the wall of the aorta tears or ruptures. Cataracts are cloudy areas in the lens of the eye. Dural ectasia happens when the tissue that surrounds the spinal cord weakens and stretches.

Market Segment Analysis

The global Marfan syndrome treatment market is segmented based on treatment type, route of administration, end-user, and region.

The aortic dilation from the treatment type segment accounted for approximately 37.3% of the Marfan syndrome treatment market share

The aortic dilation from the treatment type segment accounted for approximately 37.3%. Marfan syndrome is a relatively common heritable disorder of connective tissue that affects numerous organ systems, but the most severe complication is aortic aneurysm and dissection. A variety of medical and surgical approaches are available for managing the cardiovascular complications.

For instance, in August 2022, according to the Marfan Foundation, a meta-analysis of seven global clinical trials involving 1442 participants with Marfan syndrome found that angiotensin receptor blockers (ARBs) significantly reduce the rate of aortic root enlargement in patients. The study found that ARBs, such as losartan and irbesartan, were effective even among those already taking beta-blockers. The rate-reducing effect was particularly significant among patients with a disease-causing FBN1 gene mutation, providing biological support for the effect.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the rise in the prevalence of Marfan syndrome in the United States, advancement in treatment options, FDA approvals, novel product launches, and other factors help the region to grow during the forecast period.

For instance, in Children's Wisconsin, an estimated 50,000 people in the United States have Marfan syndrome (or three out of every 5,000 people). Marfan syndrome occurs in equal numbers in males and females and also appears equally in all races and ethnic groups. It occurs in one in 20,000 live births.

Market Segmentation

By Treatment Type

Aortic Dilation

Beta Blocker

Calcium Channel Blocker

ACE Blocker

Aortic root replacement

Valve sparing root replacement

Complex aortic surgery for dissections and aneurysms

Others

By Route of Administration

Oral

Parenteral

Others

By End-User

Hospitals

Clinics

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Mesa Science Associates Inc., Merck & Co. Inc., Aurobindo Pharma USA, Teva Pharmaceuticals, Lupin Pharmaceuticals, Inc., and AdvaCare Pharma among others.

Key Developments

In November 2023, a Pune team of eye surgeons at a city hospital successfully restored normal vision in a 35-year-old woman living with Marfan syndrome, a genetic disorder affecting connective tissue the fibers that support and anchor organs and other structures in the human body.

Why Purchase the Report?

To visualize the global Marfan syndrome treatment market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the Marfan syndrome treatment market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global Marfan syndrome treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in research and development
      • 4.1.1.2. Rise in the prevalence of chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the syndrome
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Aortic Dilation*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Beta Blocker
  • 6.4. Calcium Channel Blocker
  • 6.5. ACE Blocker
  • 6.6. Aortic root replacement
  • 6.7. Valve sparing root replacement
  • 6.8. Complex aortic surgery for dissections and aneurysms
  • 6.9. Others

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Parenteral
  • 7.4. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Mesa Science Associates Inc *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Merck & Co. Inc
  • 11.3. Aurobindo Pharma USA
  • 11.4. Teva Pharmaceuticals
  • 11.5. Lupin Pharmaceuticals, Inc
  • 11.6. AdvaCare Pharma (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us